Tagged With "Novartis"

Blog Post

LUSTER Clinical Trial Results for People With Uncontrolled Moderate-to-Severe Asthma Announced

AAFA Community Services ·
Novartis today announced topline results from its pivotal global Phase III LUSTER-11 and LUSTER-22 studies exploring the efficacy and safety of the investigational oral, once-daily, DP2 receptor antagonist fevipiprant (QAW039). The pooled analyses of the LUSTER trials did not meet3 the clinically relevant threshold for reduction in rate of moderate-to-severe exacerbation compared to placebo over a 52-week treatment period for either of the doses (150mg / 450 mg).
Blog Post

Promacta® Oral Suspension Recalled for Possible Peanut Contamination

AAFA Community Services ·
Novartis today announced a voluntary recall of three lots of Promacta (eltrombopag) 12.5 mg for oral suspension to the consumer level. The oral suspension lots are being recalled because of a risk of potential peanut flour contamination that occurred at a third-party contract manufacturing site.
×
×
×
×